Holen Sie sich die Stockscreener-App
94.23
6.19%
5.49
Handel nachbörslich:
94.23
Schlusskurs vom Vortag:
$88.74
Offen:
$90
24-Stunden-Volumen:
1.31M
Relative Volume:
0.94
Marktkapitalisierung:
$8.18B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-39.97
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
+6.14%
1M Leistung:
+27.94%
6M Leistung:
+203.48%
1J Leistung:
+515.88%
1-Tages-Spanne:
$86.60
$95.16
1-Wochen-Bereich:
$85.17
$95.16
52-Wochen-Spanne:
$14.51
$102.06
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
94.23 | 7.71B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com Australia
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Spyre gives six new hires equity awards worth 58,843 options - Stock Titan
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE) - Seeking Alpha
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - Yahoo Finance
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design - Yahoo Finance
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts - Yahoo Finance
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing - Moomoo
Spyre Therapeutics, Inc.(NasdaqGS:SYRE) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 3000 Value Benchmark - marketscreener.com
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Files for Offering up to a - Moomoo
Form S-3ASR Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com India
Form 4 Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock - Investing.com UK
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock By Investing.com - Investing.com South Africa
Spyre Therapeutics Chief Financial Officer Sold Shares Worth Over $1.3M - TradingView
Spyre Therapeutics (SYRE) CFO sells 15,000 shares after option exercise - Stock Titan
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Burrows Scott L - Moomoo
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
Spyre Therapeutics Files For Mixed Shelf Size Not DisclosedFiling - TradingView
Spyre Therapeutics files prospectus for mixed shelf - scanx.trade
Spyre Therapeutics (NASDAQ: SYRE) launches $500M at‑the‑market program - Stock Titan
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset - Seeking Alpha
Enterprise value to EBITDA forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics, Inc Actuals & Estimates (NASDAQ:SYRE) - TradingView
Enterprise value to EBITDA forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
Spyre Therapeutics, Inc Actuals & Estimates (DUS:3920) - TradingView
Enterprise value to revenue forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Price to earnings forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
Form 144 SPYRE THERAPEUTICS For: 25 June By Investing.com - Investing.com Nigeria
Price to sales forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
SYRE (NASDAQ): Affiliate files Form 144 to sell 15,000 shares on 06/25/2026 - Stock Titan
Spyre Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
SYRE Forecast — Price Target — Prediction for 2027 - TradingView
What's Going On With Spyre Therapeutics Stock On Wednesday? - Sahm
Spyre Therapeutics stock tumbles on major insider selling - Investing.com
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer |
Jul 01 '26 |
Sale |
87.74 |
7,500 |
658,040 |
97,994 |
| Sloan Sheldon | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
27.46 |
8,334 |
228,852 |
8,334 |
| Sloan Sheldon | Chief Medical Officer |
Jul 01 '26 |
Sale |
87.70 |
8,334 |
730,896 |
0 |
| Turtle Cameron | Chief Executive Officer |
Jul 01 '26 |
Sale |
87.69 |
15,000 |
1,315,346 |
582,540 |
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):